Difei Yang
Stock Analyst at Mizuho
(1.85)
# 2,907
Out of 4,829 analysts
36
Total ratings
28.12%
Success rate
4.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $2.43 | -17.53% | 4 | Mar 31, 2022 | |
| BLUE bluebird bio | Maintains: Buy | $580 → $460 | $3.51 | +13,005.41% | 3 | Sep 22, 2021 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $18.38 | +988.14% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $1.95 | +1,852.52% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $29 | $0.31 | +9,401.97% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $13.34 | +289.81% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $37.54 | +326.21% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $4.90 | +185.71% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $21 → $35 | $0.68 | +5,065.29% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.45 | - | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $7.81 | +258.51% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.10 | +1,233.33% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $2.43
Upside: -17.53%
bluebird bio
Sep 22, 2021
Maintains: Buy
Price Target: $580 → $460
Current: $3.51
Upside: +13,005.41%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $18.38
Upside: +988.14%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $1.95
Upside: +1,852.52%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $29
Current: $0.31
Upside: +9,401.97%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $13.34
Upside: +289.81%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $37.54
Upside: +326.21%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $4.90
Upside: +185.71%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $21 → $35
Current: $0.68
Upside: +5,065.29%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.45
Upside: -
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $7.81
Upside: +258.51%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $2.10
Upside: +1,233.33%